Shares of Amarin (AMRN) moved lower after the judges were posted for the company's Federal Circuit appeal of the Vascepa patent invalidation versus generics.
The appeal judges will be Timothy Dyk, Jimmie Reyna and Todd Hughes. In a research note yesterday, Piper Jaffray analyst Yasmeen Rahimi said Dyk is likely to have a favorable perspective on intellectual property appeals while Reyna is more likely to favor generics and Hughes is likely to favor patent protection rights.
Shares of Amarin are down 12%, or 85c, to $6.41 in premarket trading.
Comments
Log in or sign up to join the conversation.